---
title: "Eton Pharmaceuticals Rises After an FDA Approval But Pares Gains"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276935023.md"
description: "Eton Pharmaceuticals' shares rose initially after the FDA approved Desmoda for central diabetes insipidus management but later fell 1.5% to $18. The stock peaked at $19.98 following the announcement. Eton plans to launch Desmoda on March 9, anticipating annual peak sales of $30 million to $50 million."
datetime: "2026-02-25T20:41:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276935023.md)
  - [en](https://longbridge.com/en/news/276935023.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276935023.md)
---

# Eton Pharmaceuticals Rises After an FDA Approval But Pares Gains

By Josh Beckerman

Shares of Eton Pharmaceuticals initially rose but pared their gains after the Food and Drug Administration approved Desmoda oral solution for management of central diabetes insipidus as antidiuretic replacement therapy.

Prior to a trading halt before the company's announcement, shares were at $17.69. The stock peaked at $19.98 Wednesday afternoon but was recently down 1.5% for the day at $18.

Eton expects a March 9 commercial launch for Desmoda, an oral liquid formulation of desmopressin. The company expects product peak sales of $30 million to $50 million annually.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

February 25, 2026 15:29 ET (20:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ETON.US](https://longbridge.com/en/quote/ETON.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Key facts: FDA Approves EYLEA HD up to 20‑Week Dosing; REGN Revenue Slows](https://longbridge.com/en/news/282383303.md)
- [FDA issues complete response letter to Replimune’s RP1 for melanoma](https://longbridge.com/en/news/282511585.md)
- [<![CDATA[FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment ]]>](https://longbridge.com/en/news/282567251.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [FDA asks Lilly for more liver injury data on newly approved obesity pill](https://longbridge.com/en/news/282700321.md)